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Peroxisome proliferator-activated receptor gamma (PPARγ) is one of the most extensively studied ligand-inducible transcription
factors (TFs), able to modulate its transcriptional activity through conformational changes. It is of particular interest because of its
pleiotropic functions: it plays a crucial role in the expression of key genes involved in adipogenesis, lipid and glucid metabolism,
atherosclerosis, inﬂammation, and cancer. Its protein isoforms, the wide number of PPARγ target genes, ligands, and coregulators
contribute to determine the complexity of its function. In addition, the presence of genetic variants is likely to aﬀect expression
levels of target genes although the impact of PPARG gene variations on the expression of target genes is not fully understood.
The introduction of massively parallel sequencing platforms—in the Next Generation Sequencing (NGS) era—has revolutionized
the way of investigating the genetic causes of inherited diseases. In this context, DNA-Seq for identifying—within both coding
and regulatory regions of PPARG gene—novel nucleotide variations and haplotypes associated to human diseases, ChIP-Seq for
deﬁning a PPARγ binding map, and RNA-Seq for unraveling the wide and intricate gene pathways regulated by PPARG, represent
incredible steps toward the understanding of PPARγ in health and disease.
1.Introduction
Gene transcription requires an elaborate network of intra-
and extracellular signals, such as hormones, xenobiotics,
micro- and macronutrients (lipid metabolites, vitamins,
ions, etc.) and drugs, that converge to the nucleus following
diﬀerent pathways, resulting in the expression of each gene
in each tissue. It is a current assumption that transcription
is mostly shaped by environmental factors, acting both via
direct and indirect mechanisms. Translating exogenous and
endogenous signals which aﬀect gene transcription, into
a cellular physiological response requires the coordinated
action and the ﬁne tuning of transcription factors (TFs)
acting at DNA level, including those belonging to the nuclear
receptor (NR) superfamily [1, 2].
The human NR superfamily comprises 48 ligand-
inducible transcription factors that respond to a variety of
stimuli and are able to modulate their transcriptional activity
through conformational changes [3]. The most extensively
studied members of this TF superfamily are the Peroxi-
some proliferator-activated receptors (PPARs, also known
as nuclear receptor family 1C, NR1C). Crystallographic
studies have shown that all NRs superfamily members,
and among them PPARs, share common structural features
which include a poorly conserved N-terminal A/B domain
(with a potential transactivation domain AF-1), a highly
conserved DNA binding domain (DBD), with two zinc
ﬁnger motifs, a C-terminal region containing the ligand-
binding domain (LBD) and confer the ligand-dependent
transactivation function (AF-2), and a length-variable hinge
region between the DBD and LBD [4].
PPARs function as heterodimers with retinoid X receptor
(RXR, NR2B), and their TF activity is regulated by the
binding of ligands, the interactions with coregulators (both
activator and repressor proteins), and DNA-binding sites
[5].2 PPAR Research
In a basal state, the PPARs-RXR complex is bound to
corepressors and is transcriptionally inactive. The binding
of endogenous or synthetic ligands to the AF-2 domain
promotes a conformational change, which results in the
release of corepressors, allowing the recruitment of—and
the interaction with—coactivators [6]. These proteins either
possess or recruit proteins with, histone acetyltransferase
(HAT) activity allowing the RNA polymerase II complex to
bind and initiate transcription of target genes [4, 7].
PPAR genes are expressed in diﬀerent organs, such as
reproductive and major insulin target organs—liver, white
and brown adipose tissue (WAT and BAT, resp.), and skeletal
muscle—cardiac tissue, and others [8]. They have been
implicated in diﬀerent biological pathways ranging from
lipid and glucose homeostasis and insulin sensitization, to
c o n t r o lo fc e l lp r o l i f e r a t i o n / d i ﬀerentiation, tissue injury and
wound repair, inﬂammation, and immunity [9].
PPARs occur in three diﬀerent isotypes, termed α
(NR1C1), β/δ (NR1C2), and γ (NR1C3), encoded by three
separate genes, localized on human chromosome 22q12-
q13.1 [10], 6p21.2-p21.1 [11], and 3p25.2 [12], respectively,
and expressed in a tissue-speciﬁc manner. All three isotypes
are able to bind, with diﬀerent aﬃnities, the same consensus
response element on DNA, named peroxisome proliferator
response element (PPRE) [13]. Despite their substantial
homology and evidence of shared transcriptional targets, the
physiological functions of each PPAR are unique.
PPARγ, the best studied member of the PPAR family,
is induced during the diﬀerentiation of preadipocytes into
adipocytes and is expressed most abundantly in WAT and
BAT [14]. PPARs have a great relevance in the human
physiology, but they are also involved in the etiology of
many human diseases, and, in this contest, PPARγ is of
particular interest because of its pleiotropic functions: it
plays a dominant role in the control of the expression of a
plethora of genes related to a wide spectrum of physiological
processes, such as adipose cell diﬀerentiation, metabolism,
atherosclerosis, inﬂammation, and cancer.
Alternative promoters usage and mRNA splicing give
rise to at least seven PPARγ isoforms: the 5  end of the
mRNA consists of alternately spliced exons A1, A2, B, C,
and D in various combinations. Each splice variant diﬀers
only in the 5 -UTR: the exons at the 5  end account for
little or none of the ﬁnal translated PPARγ protein [15, 16].
In particular, the well-studied PPARγ1a n dP P A R γ2h a v e
distinct N-terminal portions, diﬀering by the presence of
extra 28 (mouse) -30 (human) amino acids for PPARγ2
isoform[17,18].PPARγ1,whoseexpressioncanberegulated
by multiple promoters (γ1, γ3, and γ4), is expressed in
all PPARγ-expressing tissues and cells whereas PPARγ2i s
almost exclusively found in adipose tissue [19, 20], where it
exerts a pronounced adipogenic activity.
Two PPARG gene 3  splice variants—lacking almost the
entire LBD— γORF4 and PPARγ1tr, have been identiﬁed as
dominant negative versus PPARγ wild type [21, 22]; hence
they are not able to promote the transactivation of PPARG
target genes.
The signiﬁcant number of PPARγ i s o f o r m s ,a sw e l la sf o r
other NRs, strongly suggests that splicing plays an important
role in the nuclear receptor functioning. Moreover, the large
number of PPARγ target genes, ligands, and coregulators
(both coactivators and corepressors) confers additional
complexity to PPARγ function. In addition, alterations in
the PPARγ trans-activating ability have to be analyzed in the
light of environmental factors, genetic background, and the
interactions among them [23].
This paper summarizes the transcriptional regulation
exerted by PPARγ on key target genes and the eﬀects of
the most frequent PPARG gene nucleotide variations on its
function,alsoapproachingtothenextgenerationsequencing
(NGS) technologies that will allow an unprecedented level of
accuracy and completeness to the study of PPARγ and other
transcription factors. Indeed, this paper describes in detail
how these novel technologies will allow to identify novel
genetic variants and polymorphisms (SNPs) in PPARG gene,
to draw high-resolution binding map of PPARγ across the
genome, and to understand the transcriptional regulation of
PPARγ-modulated genes.
2. PPARG and GeneExpression Regulation
(TargetGenes)
PPARγ controls several arrays of biological processes by
modulating the expression of speciﬁc target genes mainly
throughaligand-dependentmechanism[24].PPARγ ligands
include a surprisingly diverse set of natural ligands [25]s u c h
as prostaglandin PGJ2, linolenic, eicosapentaenoic, docosa-
hexaenoic, and arachidonic acids, and synthetic ligands,
such as the thiazolidinediones (TZDs), L-tyrosine-based
compounds, several nonsteroidal anti-inﬂammatory drugs,
and a variety of new chemical classes.
The PPARs, and PPARγ among these, like many non-
steroid members of the NR family, function as obligate
heterodimers with RXRs [26]. The heterodimers are able
to bind PPRE, consisting of direct repeats of the canonical
AGGTCAhalf-siteseparatedbyonebasepair(DR1)together
with the upstream speciﬁcity element AAACT [13, 27].
Typically, RXRs do not function alone but rather serve as
master regulators of several crucial regulatory pathways, in
combination to diﬀerent NRs’ partners.
Recently this issue has been better elucidated through the
use of standard chromatin immunoprecipitation (ChIP)
coupled with massive sequencing on NGS platform (de-
scribed more in detail in Section 4.2 entitled “Transcription
Factors and ChIP-Seq”) [28]. In this study the authors pro-
ﬁled PPARγ- and RXR-binding sites throughout adipogenic
diﬀerentiation (Figure 1). They identiﬁed diﬀerential spatial
and temporal recruitment of PPARs and RXR to target sites
during adipogenesis; in particular, at the onset of diﬀer-
entiation the DNA occupancy by RXR alone was detected.
Interestingly, immediately afterwards, many of these sites
become occupied by RXR and PPARδ, lowly expressed into
adipocytes. Moreover, through the early days of diﬀerentia-
tion, they observed a diﬀerent temporal and compositional
pattern of occupancy with a switch between PPARδ and
PPARγ, which becomes the main RXR partner throughout
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Figure 1: Novel insight into PPARG world trough new approaches. In the presence of ligands (upper), PPARγ binds to its PPRE as
heterodimerwithRXRtoactivateorrepresstargetgenes’expression.TheﬁguresummarizesnovelmolecularmechanismsofPPARγ obtained
through ChIP-seq. PPARγ- and RXR-binding sites detected by ChIP-seq reveal diﬀerent spatial and temporal activation of distinct metabolic
pathwaysandchangesinRXRdimercompositionduringadipogenesis(rightpanel,studyfrom[28]).PPARγinAdipocytesandMacrophages:
tissue-speciﬁcregulatoryregionsemploycell-type-speciﬁccoregulators,C/EBPβ inadipocytesandPU.1inmacrophages(lowerpanel;ChIP-
Seq study from [31]).
both PPARγ1a n dP P A R γ2 expression [28–30]. The binding
of RXR alone—in the early stage of diﬀerentiation—on
the target sites later bound by PPARγ:RXR complex has
been hypothesized to serve as a signature needed for
subsequent PPARγ-dependent binding and/or activation of
transcription for target genes [28].
The modulation of transcription depends on the recruit-
ment of cofactors able to remodel the chromatin struc-
ture making it more accessible to the basal transcription
machinery recruitment and assembly at the core promoter
of target genes [32, 33]. Indeed, it has been widely assumed
thatchromatinaccessibilitytothetranscriptionalmachinery,
through histone modiﬁcations (acetylation, methylation,
phosphorylation, ubiquitylation, sumoylation, deimination,
ADP ribosylation, and proline isomerization) represents, a
very relevant process into gene expression regulation [34–
37]. In light of this, the diﬀerent temporal—and com-
positional pattern—of occupancy on these binding sites,
observed by Nielsen and colleagues (2008) [28]i sl i k e l y
to be required for the chromatin remodeling to such loci,
rendering these regions accessible for PPARγ:RXR binding
and the subsequent transactivation of target genes.
Although PPARγ:RXR heterodimer controls the expres-
sion of many inducible genes, transcription is regulated
both globally and locally by diﬀerent factors. Determining
which cell-speciﬁc coactivators/corepressors are recruited by
PPARγ in diﬀerent cell types, and how these may contribute
to chromatin modiﬁcations and diﬀerential gene expression,
represents a crucial issue for fulﬁlling our gap towards the
understanding of PPARγ biology and function.
Thecurrentlyassumeddogma,mostlyreferredtoallTFs,
is that the cell-type-speciﬁc trans-activating ability is due to
the cooperative binding to other cell-type-selective factors,
which speciﬁcally “drive” the TF to its target genes.
However, although it is well known that PPARγ is able
to modulate target genes’ expression in some cell types but4 PPAR Research
not others, the molecular mechanisms underlying its ability
are not yet well elucidated. Diﬀerential binding of PPARγ to
the PPRE of target genes or its diﬀerential activity at DNA
level (i.e., in chromatin remodelling) has been claimed as the
putative mechanisms accounting for the cell-type speciﬁcity
of its action [38].
A very recently published work of Lefterova and col-
leagues (2010) [31] has provided novel intriguing insight
into the molecular basis of cell-type-speciﬁc gene expres-
sion in primary mouse adipocytes and macrophages. The
authors, by using ChIP-Seq (see Section 4.2), identiﬁed the
molecular signatures of PPARγ binding, disclosing distinct
macrophage-andadipose-speciﬁcPPARγ-bindingsitesover-
all the genome. Moreover, they shed light on the cell-
speciﬁc expression of PPARγ target genes, demonstrating the
tight and well-regulated cooperation of PPARγ and other
crucial cell-type-speciﬁc proteins (PU.1 and C/EBPb, nearby
macrophage- and adipocyte-speciﬁc target genes, resp.) (see
Figure 1). “PPARγ dances with diﬀerent partners” [38],
and all the biological processes PPARγ-modulated can be
thus attributed to a diﬀerential recruitment of coactivators
and corepressors functioning as scaﬀolds for chromatin
remodelling enzymes.
The coactivators of PPARγ include well-established
cofactors such as p300/CBP, p160, and PGC-1 (PPARγ
coactivator-1), as well as TRAP220 (thyroid hormone
receptor-associated protein 220 or PBP, PPARγ-binding
protein) [39, 40], ARA70 (Androgen Receptor-Associated
protein) [41], and PRIP (PPARγ-interacting protein, ASC-
2/RAP250 /TRBP/NRC) [42].
In the absence of ligand, PPARγ recruits corepressors
such as silencing mediator for retinoic and thyroid hormone
receptors (SMRT) and the nuclear receptor corepressor
(N-Cor), which bind repressive enzymes such as histone
deacetylase enzymes (HDAC), and particularly HDAC3
[43] or the histone methyl transferase (HMT) SUV39H1,
which speciﬁcally methylates histone H3 at lysine 9 (H3K9)
[44]. RIP140 (receptor-interacting protein) may also be a
component in the corepressor complex [45, 46]. The ability
of PPARγ to repress transcriptional responses to diverse
signaling pathways is an essential aspect of its biological
activities, but mechanisms determining the speciﬁcity and
functional consequences of the process known as tran-
srepression remain poorly understood. However, PPARγ
can also inﬂuence gene expression independently of its
binding to the PPRE. Indeed, PPARγ-dependent repression
ofinﬂammatorygeneexpressionoccursthroughinterference
with the action of NF-kB via transrepression [47]. Moreover,
the activity of other transcription factors, for example, AP-1
andSTAT-1,canbeinhibited byPPARγ viadirectinteraction
or by competition for limiting supplies of coactivators [48].
PPARγ transactivation ability is induced by ligand-
dependent and independent mechanisms. The AF-1 domain
of PPARγ is the ligand-independent activation domain that
regulates the speciﬁcity of PPARγ transcriptional activity
during adipogenesis [49] .T h ep r e s e n c eo fa ne x t r a3 0
aminoacids in the AF-1 domain of PPARγ2 isoform that
makes it a better transcriptional activator than PPARγ1[ 50].
Indeed, it was shown that PPARγ2i sa b o u t1 0t i m e sm o r e
active than PPARγ1 in ligand-independent transcriptional
activation, through this domain [50, 51]. Thus, PPARγ1a n d
PPARγ2m a yh a v ed i ﬀerent functions, with PPARγ1 being
used when the ligand is abundant whereas PPARγ2w o u l d
be crucial under conditions of low ligand concentration,
such as it might occur in early adipocyte diﬀerentiation [51].
However, the ligand-independent transactivation through
the AF-1 domain, common to PPARs, is poorly understood
and beyond the scope of this paper.
2.1. PPARG-Modulated Pathways: Obesity and Inﬂammation.
The biological activities of PPARγ a r ev e r yw i d eb u ti t
is generally acknowledged as a transcriptional regulator of
lipid and glucose metabolism, since it is highly expressed in
adipocytes and controls the expression of several adipocyte-
speciﬁc genes involved in lipid synthesis and storage, insulin
signalling, and adipokine production [52, 53].
PPARγ−/− mice models, with selective ko in three
metabolic tissues (adipose tissue, skeletal muscle, and liver),
have revealed that PPARγ is a master regulator of adipoge-
nesis; PPARγ deﬁciency and/or partial disruption in any of
these tissue severely aﬀects whole body lipid homeostasis,
altering insulin sensitivity. The essential role of PPARγ in
adipogenesis was revealed by inactivation of both PPARγ1
and PPARγ2 in the adipose tissue [54, 55].
PPARγ2 depletion was shown to dramatically diminish
adipose tissue (WAT) mass—due to a strongly reduced
adipocyte diﬀerentiation observed also in vitro—providing
protection against high-fat-diet induced weight gain and to
determine an impairment of insulin sensitivity [56]. In this
context, a common aminoacid polymorphism (Pro12Ala) in
PPARγ2 (described in detail in the next section) has been
associated with type 2 diabetes and has been suggested to
induce a modest impairment of transcriptional activation
due to decreased DNA-binding aﬃnity [57].
ConﬂictingresultshavebeenreportedbyMedina-Gomez
and colleagues (2005) [58]. Although they observed a clear
in vitro defect in fat cell diﬀerentiation, they demonstrated
thatPPARγ2-depletionisdirectlylinkedtoinsulinresistance,
without alteration of in vivo adiposity, even in presence of a
high-fat diet. The possible explanation of a residual presence
offatdepotsinthesekomicestronglysuggestedthatPPARγ1
was able to initiate, at least in part, adipocyte diﬀerentiation.
In addition, it has been shown a global deregulation in the
repartitioning of lipids in these mice models. A complex
cross-talk between these metabolically active tissues (liver,
adipose tissue, and muscle) appears to be essential for energy
balance.
Other studies have demonstrated that mouse models of
heterozygous PPARγ (PPARγ−/+), with a decreased PPARG
geneexpression,showimprovedinsulinsensitivitycompared
to wt mice [59, 60] although the reduced PPARG gene
expression was associated with decreased metabolic rate and
physical activity [61]. Reduction of PPARG gene expression
in the PPARG−/+ mouse model is associated with a mild
decrease in PPARγ protein levels [62], suggesting that
modulation of PPARγ protein levels, rather than mRNA
itself, may play a role in determining PPARγ activity in
adipocytes. Indeed, regulation of PPARγ protein translationPPAR Research 5
is expected to be tightly regulated. Althoguh a moderate
decrease of PPARγ protein may protect against high-fat diet-
induced insulin resistance, its complete lack in adipocytes is
deleterious to lipid and glucose metabolism as well as insulin
sensitivityinthepresenceofahighfatdiet,asshowninmost,
but not all, studies of adipose-speciﬁc PPARγ knockout
mouse models [63].
Ac o n s i d e r a b l er o l ef o rP P A R γ in macrophage lipid
metabolism has been also clearly demonstrated [64]. The
involvement of PPARγ in regulating lipid metabolism in
macrophages was initially suggested by the discovery of
CD36, member of scavenger receptor family that medi-
ates uptake of oxidized LDL, as a PPARγ target gene in
macrophages [65].
PPARγ has a similar function in macrophages and
adipocytes as it modulates lipid homeostasis in both cell
types via regulation of genes including LPL (lipoprotein
lipase),ACAT (acetylcoenzymeAacetyltransferase)andPLA
(phospholipase A) genes, and the levels of FFAs (free fatty
acids), PGs (prostaglandins), and LTs (leukotriens). PPARγ-
deﬁcient mice have provided clues to an antiatherogenic
role of PPARγ since these mice showed a signiﬁcantly
impaired lipid homeostasis in the arterial wall and enhanced
atherosclerosis development [66, 67]. The molecular mech-
anisms underlying the antiatherogenic properties of PPARγ
involve stimulation of cholesterol eﬄux from macrophages
into the plasma and inhibition of monocyte recruitment
into the developing atherosclerotic lesion [67]. Interestingly,
macrophage-speciﬁcablationofPPARγ resultedinhighrates
of insulin resistance suggesting that macrophage PPARγ may
exert a protective role in obesity [68].
Indeed, it is becoming always more evident a functional
link between macrophage activity, inﬂammation, adipose
tissue, and type 2 diabetes mellitus (T2DM) [69, 70].
In a physiological state, macrophages residing in fat mass
are responsible for keeping in the adipose tissue an anti-
inﬂammatory environment, conferring an adequate degree
of insulin sensitivity. In pathological conditions, such as
obesity, adipose tissue is continually under metabolic stress,
leading to the constitutive activation of stress and inﬂamma-
tory pathways, resulting in macrophage accumulation within
the adipose tissue. Proinﬂammatory macrophages inﬁltrate
adipose tissue, exacerbating local inﬂammation and giving
rise to insulin resistance [31]. In this scenario, even though
PPARγ is not required for macrophage diﬀerentiation or
phagocytic activity, its deﬁciency is associated with the con-
stitutive onset of an inﬂammatory milieu, in turn resulting
inanenhancedsusceptibilitytodiet-inducedobesity,glucose
intolerance, and insulin resistance [31].
All these ﬁndings indicate the crucial role of PPARγ in
adipocytes as well as macrophages, although, to date, only
two studies [28, 31] have analyzed in-depth the localizations
and mechanism of PPARγ recruitment within this cells,
trying to address these quite complicated but fundamental
questions.
The recent technological advances—such as high-
throughput sequencing methods and innovative techniques
for following the three-dimensional interactions of chromo-
somes in the nucleus—a ll o wt ora p i dl yu n c o v e rn e wl a y e r so f
complexity within PPARγ world. By using these approaches,
it would be of interest to analyze the selective pattern of
PPARγ activity within speciﬁc cell types, with the ﬁnal aim
to understand how its alterations may aﬀect human health.
Several studies have been performed about PPARG gene
anditsmainisoforms,namely,PPARγ1and-γ2,eventhough
other variants have been disclosed [16, 21, 22]. In the near
futureitwouldbeofgreatrelevancetoaddressalsotheroleof
newly described isoforms in physiologic as well as pathologic
conditions.
However, the phenotypic eﬀects described for human
PPARγ variants, and various mouse models with altered
expression of PPARG mRNA, and often conﬂicting results
from diﬀerent studies so far performed, unequivocally depict
a highly complex picture of PPARγ functions and biology.
3. PPARG Target Genes:Polymorphisms,
Haplotypes,andGene Expression
PPARGgene nucleotide variations, and their possible pheno-
typeconsequences,havebeenwidelyandconverselyanalyzed
in the last two decades [7, 23, 71, 72]. Since PPARγ is a
transcriptional factor involved in the regulation of several
target genes in many tissues, the primary consequence of a
geneticvariantislikelytobeanalterationofexpressionlevels
of target genes.
Although the impact of common single nucleotide
polymorphisms (SNPs) in PPARG gene on the expression
of its target genes is not fully understood, an SNP and/or
a combination of them (haplotype) may aﬀect the PPARG
transcript itself and in turn its ability to regulate gene
expression [23].
What does really happen to PPARγ activity in the
presence of a DNA polymorphism and/or mutation? Few
studies have directly considered the real eﬀect of PPARG
variants on the PPARG expression itself and of its target
genes, evaluating the alteration of its binding aﬃnity to
PPRE, the promoter eﬃciency, and other factors that may
aﬀect its transactivation ability [73–84].
Indeed, most of the studies about nucleotide variations
in PPARG have mainly focused on the association between
a DNA variant and a speciﬁc phenotype (such as predictors
of diabetes, obesity, and BMI) [57, 85–89] or related
biochemical markers (plasma levels of hormones, peptides,
or metabolites) demonstrated—or just supposed—to be
transcriptionally regulated by PPARγ itself [78, 90–102].
The most widely studied SNP in PPARG gene [57, 72,
73, 83], Pro12Ala, occurs in PPARγ2 isoform and has been
very often associated to clinical consequences and several
alterations of physiological metabolic status [57, 72, 73, 85–
87, 89, 103]. About the direct eﬀect of this polymorphism
on PPARγ activity, some functional studies have revealed
that Pro12Ala confers to PPARγ2 a decreased binding
aﬃnity to PPRE and a reduced transactivation ability, both
in a luciferase reporter gene assay and in TZD-induced
adipogenesis [73, 75].
Ithasbeenalsoshownthatinhumanadiposetissuethere
were no signiﬁcant diﬀerences in the basal expression levels6 PPAR Research
of some PPARγ target genes (UCP-2, LPL, p85aPI3K, and
PPARγ1) between obese Pro12Ala and Pro12Pro carriers,
except for a reduction of about 40% observed for p85aPI3K
gene in the omental fat [78].
To explain the observed discrepancies, between in vitro
and in vivo studies, Kolehmainen et al. speculated that
subjectsAla12homozygoushavemorerelevantdiﬀerencesin
gene expression activation compared to Ala12 heterozygous;
moreover, it must be considered the interaction of genetic
and environmental factors and observed tendency for a
higher expression of PPARγ2 in the subcutaneous fat depots
of Pro12Ala carriers [78].
In addition, Heikkinen and colleagues (2009) [83]h a v e
recently highlighted the importance of metabolic context in
modulatingPro12Alaeﬀects,reportingorconﬁrmingseveral
associations between this PPARG variant and phenotype
traits (Table 1). They have shown that in WAT of Ala/Ala
mice some genes were downregulated, whereas a great
number of genes were upregulated in muscle. Further-
more, they have interestingly suggested that Pro12Ala might
be implicated in G protein function, in sensitization of
adiponectinsignalingandalteredcofactorsrecruitment[83].
To investigate how Pro12Ala might inﬂuence gene
expression of molecular targets and in turn the response to
exogenous stimuli, the functional properties of N-terminal
domain should be also considered. In particular, this SNP
occurs at position 12 in the N-terminal region of PPARγ2
and shows diﬀerent transactivation ability than PPARγ1,
diﬀering only in its N-terminus. As mentioned above, the
additional residues at N-terminus of PPARγ2, encoded by
the exon B, confer a trans-activating ability up to tenfold
greater than PPARγ1, indicating that γ2i s o f o r mi sm o r e
potent to induce the expression of target genes in the absence
of activating ligands [50]. Pro to Ala amino acid change
might aﬀect the secondary structure of the protein and
consequently its functionality [110]. Indeed, it has been
recently shown that proline residues, although counteracting
α-helix formation, ﬁt well only into N-terminal of α-helices,
positively modulating the proteins’ stability [111].
The direct relationship between PPARγ transcriptional
ability and an SNP in the regulatory region of PPARG gene,
C-2821T, was reported by Muller and colleagues (2003)
[79] in the Pima Indians population. This polymorphism,
in strong linkage disequilibrium (LD) with Pro12Ala, falls
within a putative E2-box in a binding site for δEF1, a
transcriptional repressor. Since it has been shown that C-
2821T confers to PPARγ an increased transcriptional ability
[79], this SNP might be responsible for a decreased binding
aﬃnity between δEF1 and E2-box or for a reduced complex
stability. Although the mechanism by which these alleles in
LD (−2821T and Ala12) function remains uncertain, taken
together these ﬁndings suggest that Ala12 may alter PPARγ2
transactivation ability, and −2821T may alter transcription
of PPARγ2 isoform [79]. Other nucleotide variations, most
of them gain- or loss-of-function mutations, have been
described in PPARG gene.
Afunctionalstudyaboutararegain-of-functionPPARγ2
mutation, Pro115Gln, highlighted the relevance of phospho-
rylation at Ser 114 in reducing PPARγ activity; this variation
in the ligand independent activation domain of PPARγ
aﬀects phosphorylation and renders PPARγ constitutively
active, according to increased body mass index (BMI)
observed in obese individuals [71, 108].
Another PPARG nucleotide variation, aﬀecting PPARγ
function,occursinthesamedomain:arareframeshiftmuta-
tion,[A553ΔAAAiT]fs.185[stop186],resultinginatruncated
protein in the DBD [76]. Within the same family, this
premature stop codon was found in all individuals with
insulin resistance and metabolic syndrome (MS), carrying
also a similar mutation ([C1984ΔAG]fs.662[stop668]) in
PPP1R3A (protein phosphatase1- regulatory subunit 3) [7,
76, 82]. This frameshift is a loss of function mutation
that aﬀects heterodimers formation and PPARγ interaction
with PPRE in target gene promoters, resulting in a failed
transactivation [76].
Ithasbeenshown,invitro,thatfourraremutationsinthe
LBD of PPARγ result in a reduced PPARγ trans-activating
ability in the presence of a synthetic ligand, aﬀecting its
ability to recruit cofactors, ligands, and RXRα: Pro495Leu
(also called Pro467Leu), Val318Met (also called Val290Met),
Phe388Leu, and Arg425Cys (Table 1)[ 7, 71, 74, 77, 81, 109].
The ﬁrst two mutations aﬀect two helices critical for the
recruitment of ligand and cofactors and have dominant-
negative activity against wild-type PPARγ. The latter, in
contrast, are haploinsuﬃcient mutations, occurring in a
hydrophobic region that interacts with RXRα and ligands
[7, 71].
Inamorerecentstudy,otherraremutations,occurringin
DBD—Cys114Arg, Cys131Tyr, and Cys162Trp—and in LBD
−315Stop and Arg357X—of PPARγ, have been described.
These variants encode proteins unable to bind DNA, which
lackthetransactivationabilityandshowadominantnegative
activity consisting in the competitive recruitment of coacti-
vators with wild-type PPARγ (see Table 1)[ 82].
Furthermore, we recently reported a novel dominant
negative mutation in PPARγ LBD, Ser289Cys, associated
with colorectal cancer, dyslipidemia, hypertension, and
overweight, but no with T2DM. The formation of an
S-S bridge, between Cys289 and Cys285, might impede
agonist positioning, explaining the demonstrated reduction
of transactivation ability of mutant protein [84].
Although some studies have demonstrated the func-
tional impact of PPARG nucleotide variations on protein
activity and/or stability and on its ability to trans-activate
target genes, most of PPARG variants have been associated
with clinical eﬀects [71, 88, 89] or plasma levels of a
protein without investigating PPARG expression, isoform
abundance, and mRNA levels of target genes. These non-
functional association studies do not prove—allowing just to
hypothesize—the altered expression of PPARG target genes.
Moreover, it has been demonstrated that gene-gene and
gene-environment interactions (i.e., diet, exercise, and age of
onset of the disease) may greatly aﬀect the contribution of a
speciﬁc SNP to the resulting phenotype.
Taken together, these considerations contribute to
explain the conﬂicting results about PPARG nucleotide
variations obtained in diﬀerent populations [57, 73, 78, 85–
89, 104, 108, 110, 112–115].PPAR Research 7
Table 1: Nucleotide variations within coding and regulatory regions of PPARG.




Conﬂicting results about association to T2DM and
insulin resistance. When in LD with C1431T no
protection from T2DM development
[57, 73, 83, 85, 87, 89, 102, 104, 105]
Cardiac disease Decreased incidence of cardiac disease [103]
HDL Higher HDL cholesterol [73]
BMI
Reduction of BMI and fat and lean mass in nonobese
(potentiated when in LD with C1431T) and BMI
increase in obese individuals
[73, 83, 86, 91, 106]
LPL Reduced LPL activity and levels. [83, 93]
Leptin Increased leptin levels [92, 100]
Adiponectin Reduced adiponectin levels [94, 96, 98, 101]
Resistin Reduced resistin levels [97, 102]
Bone features Increase of total bone area and bone mineral content






Increased BMI and fat mass.
Reduced risk of T2DM.
Increased leptin levels.
Increased resistin levels.
[88, 90, 91, 102, 107]
Pro115Gln BMI Increased BMI in obese individuals [108]
[A553ΔAAAiT] Insulin resistance T2DM
Hypertension
In association to 662stop668 mutation in PPP1R3A
is responsible of variable hyperinsulinemia, T2DM,









Severe insulin resistance, TD2M, and early-onset
hypertension.
Dyslipidemia, preservation of abdominal fat with
selective loss of gluteal and limb subcutaneous fat;
inability to trap and store NEFA in the postprandial





Lipodystrophy and dyslipidemia less severe, with
absence of fat depots on the upper arms,
phlebectasia of limb veins and of hepatic steatosis.
Atherosclerosis, polycystic ovarian disease, increased




Diabetes mellitus and hypertriglyceridemia previous
to the development of limb and facial lipoatrophy;
loss of subcutaneous fat, except for sc truncal fat.









Reduced body fat, partial lipodystrophy of limb and
gluteal depots, insulin resistance, hepatic steatosis,
severe dyslipidemia, increased triglycerides levels,
low HDL levels.




Colonic lesions, reduced restraint of cell
proliferation both in vitro and in vivo, interference
with the inﬂammatory pathway in tumor tissues and
proximal normal mucosa
[84]
A-2819G T2DM and diabetic
retinopathy
Association with T2DM and proliferative






Increased LDL levels. [95, 99]
A-14G Partial lipodystrophy
MS
−14G associated with familial partial lipodystrophy
subtype 3 (FPLD3). It has been found MS and a
relative reduction of gluteal and extremities’fat.
[80]8 PPAR Research
For instance, Pro12Ala has been often associated with
several diseases and phenotype eﬀects [7, 71, 72], such
as increased protection from T2DM onset and insulin
resistance, decreased incidence of cardiac disease, higher
HDL cholesterol, reduction of BMI in nonobese individuals
[57, 73, 85, 87, 103], and increased BMI in obese individuals
[86, 91]. A recent study in Russian population supports the
association of Pro12Ala with improved insulin sensitivity
and the protection from T2DM [89]. Moreover, a recent
meta-analysis of 60 association studies also conﬁrms the
association between Ala12 allele and reduced T2DM risk
[110].
In contrast, two recent conﬂicting studies in the Indian
population have shown that Pro12Ala contributes to T2DM
development [105] and do not exhibit any association
with MS, T2DM, and obesity, respectively [102]. Gene-
environment and gene-gene interactions might strongly
contribute to the diﬀerent Pro12Ala eﬀects observed in the
studied populations [23, 116].
This SNP has been also associated to altered plasma
levels of LPL, leptin, adiponectin, and resistin. Indeed, it was
shown, in vivo, that Ala12 allele is associated with a reduced
LPL activity in postheparin plasma [93]; higher leptin levels
were observed in Pro12Ala compared to Pro12Pro carrier
women [92]. The eﬀect of Pro12Ala on increased leptin
levels is likely to be supported by a study in women with
functional hyperandrogenism (FOH), in which the authors
demonstrated that Ala allele was more frequent in FOH
women than in healthy controls (36% versus 28%) and that
leptinlevelswerehigherinnonobeseFOHwomencompared
to controls [100].
Also the association between Pro12Ala and adiponectin
plasmalevelsseemscontroversial:intheJapanesepopulation
Ala12 allele is associated with reduced serum adiponectin
levels [94, 96] whereas no signiﬁcant eﬀect of this poly-
morphism on serum adiponectin was observed in polycystic
ovary syndrome, healthy women, and in Asian Indians [98,
101].
In a study by Wang et al. (2004) in [97], it has
been reported that Ala12 allele might aﬀect the expres-
sion of a gene RETN encoding another adipose tissue-
related molecule, the resistin, in the Chinese population;
both heterozygous and homozygous Ala12 carriers showed
lower plasma resistin levels compared to homozygous Pro12
carriers [97]. On the opposite, a recent report in an Indian
populationdescribednostatisticallysigniﬁcantdiﬀerencesin
resistinplasmalevelsbetweenPro12andAla12carriers(both
heterozygous and homozygous) [102].
Pro12Ala has been described in linkage disequilibrium
(LD) with another common PPARG variant, C1431T; this
silent SNP, occurring in the exon 6, is also known as
His477His and C161T of exon 6 [71]. It has been observed
that when Pro12Ala is in LD with C1431T SNP, its protective
eﬀect on T2DM development disappears [87], while the
consequences on BMI are potentiated [106].
The lack of functional ﬁndings within the above-
described association studies and possible inﬂuence of
ethnicity, environmental and genetic factors are likely to
explain the controversial results so far reported. Moreover,
due to LD between polymorphisms, determining the relative
contribution of each SNP on the resulting phenotype is quite
diﬃcult.
For instance, diﬀerent studies report that 1431T allele
is associated with an increased BMI in obese Finns [91], a
reduced risk of diabetes in a large Asian population [107],
and not at all associated with T2DM, obesity, and BMI
alteration [88].
About its eﬀects on plasma proteins levels, C1431T
has been associated with increased leptin levels [90]. Also
Valve et al. [91] observed higher leptin levels in the obese
women with C1431T than other obese women studied; this
polymorphism was associated with increased fat mass, and,
albeitinthisstudy,theauthorshypothesizethathigherleptin
levels were entirely due to increased adipose tissue mass
and not directly linked to PPARγ-dependent transcriptional
regulation [91].
Moreover, also resistin levels were signiﬁcantly increased
in individuals carrying C1431T whereas the Pro-C haplotype
was more frequent in groups with lower resistin levels.
In contrast, Pro-T and Ala-T haplotypes showed increased
frequency in groups with higher resistin levels although
statistically not signiﬁcant [102].
Moreover, nucleotide variations in putative regulatory
regions of PPARG have been associated, with diﬀerent
extents, to human diseases. Indeed, we recently identiﬁed A-
2819G SNP in PPARG promoter and observed a signiﬁcant
association with T2DM and proliferative retinopathy in
diabetic females whereas no linkage disequilibrium with
Pro12Ala nor association with obesity was observed [88].
It has been hypothesized that this SNP might alter PPARG
transcript abundance inﬂuencing in turn the expression
levels of some PPARγ targets involved in the eye physiology
[88].
Other three variants in PPARG putative promoter have
been identiﬁed: A-14G, C-681G, and C-689T [71], even
though their impact on PPARG transcription and function
has not been completely elucidated. These polymorphisms
may possibly aﬀect the expression of some PPARγ molecular
targets, since C-681G and C-689T were associated with
increased plasma LDL levels and A-14G with a decreased
activity of PPARγ4p r o m o t e r[ 80, 95, 99].
The introduction of massively parallel sequencing plat-
forms, which have oﬀered to researchers the possibility to
identify,inasingleexperiment,pointmutationsand/orgross
genomic rearrangements, within coding and yet unexplored
regulatory regions of disease-causing genes, will surely rep-





Any genetic information is conveyed from DNA to proteins
via mRNA, through a complex and ﬁnely regulated pro-
cess. Unraveling how these genomic information are then
translated into gene regulation has been for many decadesPPAR Research 9
an intriguing ﬁeld, fulﬁlled by many advances, speculations,
and scientiﬁc debate. To achieve this tuned regulation, the
concerted action of multiple cis-acting proteins, able to
speciﬁcally bind cis-regulatory elements, such as promoters
and enhancers, is needed [2, 117]. Moreover, since the
basal transcriptional activity, resulting from the binding
of so-called general TFs to the core promoter, is usually
low, diﬀerent site-speciﬁc TFs participate to the recruitment
and/or thestabilization ofgeneralTFs’complexes,increasing
the cell transcriptional rate. Moreover, histone-modifying
enzymesmayberecruitedbyotherfactors—bindingtodistal
enhancer regions—and determine a favourable chromatin
environmentandasubsequenttranscriptionalenhancement.
On the other hand, the transcription can be negatively
modulated through the binding of repressive factors to distal
silencer regions or the competition with TFs themselves.
TounderstandPPARγ-mediatedphenomenainaspeciﬁc
cell/tissue/organ one cannot ignore the consideration that
PPARγ is a transcription factor. Its mechanistic understand-
ing represents a prerequisite for ﬁne-tuning the therapeutic
activities of PPARG.
Moregenerally,severalhumandiseaseshavebeendirectly
linked to alterations in the gene expression caused by defects
in the structure and/or function of a key transcriptional
regulator [2] although it is arguable that many other “TF-
disease associations” still remain to be identiﬁed. Expanding
our understanding of how site-speciﬁc TFs contribute to
gene expression regulation, and in turn how alterations in
both TF structure and activity may account for a speciﬁc
disease phenotype, appears to be a crucial endpoint.
In this context, the speciﬁc case of PPARγ is not
an exception, rather it is likely to be one of the most
representative candidate genes in “TF-disease” association
studies, for its involvement in many physiological and also
pathological processes [7].
To this aim, the introduction of massively parallel
sequencing platforms in the 2004, coupled with the recent
advances in chromatin immune-precipitation (ChIP) fol-
lowed by sequencing (ChIP-seq), has clearly revolutionized
the way we approach to—and also study—diﬀerent bio-
logical phenomena [118–121]. Although all the sequencing
platforms commercially available use diﬀerent sequencing
chemistry and methodological procedures, also varying in
the number of sequenced reads, read length and error
characteristics, they all are based on the generation of
libraries to sequence, and the miniaturization of individual
sequencingreactions[121].Unlikepreviouslyusedtag-based
sequencing methods, such as Serial and Cap Analysis of
Gene Expression (SAGE and CAGE, resp.), Polony Multiplex
Analysis of Gene Expression (PMAGE), NGS libraries do not
require a prior step of cloning before sequencing. Moreover,
a common feature of NGS platforms is the template binding
to a solid surface or support (immobilization by primer
or template) or its indirect immobilization (by linking a
polymerase to the support) [122]. However, whatever are the
sequencing chemistry and the methodological procedures
used, a single NGS platform can generate a large amount of
dataupto2gigabases(Gb)ofsequencereadsperday,shifting
the eﬀort of researchers from biology to bioinformatics.
These platforms have been quickly applied to many sci-
entiﬁc contexts, giving rise to many “Seq” protocols, specif-
ically developed and suited for a particular research branch,
from transcriptomics (RNA-Seq) to the targeted resequenc-





changed the way we think about many scientiﬁc issues, one
of the broadest and useful applications of this technology is
towards the identiﬁcation of the genetic causes of inherited
diseases, both mendelian and multifactorial.
In light of this, deeply investigating PPARG—from
DNA variations to gene expression and its regulation—will
surely enhance our understanding about its involvement in
health and disease. Identifying novel nucleotide variations,
both point mutations and gross genomic rearrangements,
within coding regions and yet unexplored intronic and
regulatory regions of PPARG by targeted resequencing (on
NGS platforms) will be the ﬁrst brick towards building a
more complete and detailed view of PPARG function and
activity(summarizedinFigure 2).Inaddition,thepossibility
to identify the exact position of its binding sites and thus
draw a complete high-resolution binding map across the
genome (by ChIP-Seq) [123, 124], combined with the large
amount of useful whole transcriptome data obtained by
RNA-seq, will provide an unprecedented level of accuracy
and complexity than ever done (see Figure 1)[ 125].
4.1. NGS for the Targeted Resequencing. The whole genome
resequencing of aﬀected individuals’ genomes by the use
of NGS platforms is likely to represent the most power-
ful approach to identify single nucleotide variants and/or
genomic rearrangements (insertions, deletions, and copy
number variations) within disease-causing genes. Nonethe-
less, it is clear that such genome-wide approach cannot be
used for a routine mutational screening in wide number
of aﬀected individuals, due to the high computational and
economic eﬀort required, particularly considering that there
are few research groups in big companies and/or large
corporations, as well as big public and private world leading
research institutions, able to sustain these costs.
Thus, targeted resequencing of a small number of
candidate genes or disease loci appears to be the only reliable
way to obtain the high accuracy of NGS data at the accessible
costs of a standard array analysis. On the other hand, it
appears crucial to have eﬃcient and cost-eﬀective capture
methods to enrich the sample with “high-value” genomic
regions to sequence in order to avoid oﬀ-target sequencing.
In light of this, diﬀerent techniques have been recently
developed allowing researchers to enrich their sample of
target genomic regions to be further sequenced. Multi-
plex PCR ampliﬁcation of speciﬁc target regions was ﬁrst
used for candidate gene approaches, to enrich the sam-
ples with regions of interest, further processed to prepare
libraries prior to sequencing [126–128]. Another approach












Figure 2: Innovative approaches by using next generation sequencing technologies. Next generation sequencing can be applied to many
scientiﬁc contexts: targeted resequencing for the identiﬁcation of disease-causing nucleotide variations for both coding and unexplored
regulatory regions of genes (CNV-Seq and DNA-Seq); ChIP-Seq, for DNA-protein interaction studies coupling chromatin immuno-
precipitation(ChIP)andmassivelyparallelsequencing;RNA-Seq,forwholetranscriptomestudies,includingexpressionlevelsofknownand
yet unknown transcripts (both coding and non-coding), diﬀerential splicing, allele-speciﬁc expression, RNA editing, and fusion transcripts
(see review [121]).
capture approaches (custom in-situ synthesized oligonu-
cleotide microarrays) have been successfully used to enhance
the sequencing template enrichment [130–133]. Companies,
such as NimbleGen, have recently developed microarrays
for the capture-by-hybridization of thousands of predeﬁned
genomic regions, mainly coding regions (exons), widely
used for targeted resequencing experiments [134]. Several
research groups have clearly shown that the above-described
capture methods are playing a crucial role in driving targeted
resequencing applications of NGS platforms [129].
Since most of human genetics studies have so far mainly
focused on protein-coding exons, these regions usually
represent high-value targets for targeted resequencing, even
though this approach can be—and we believe in most
cases it must be—extended to gene regulatory regions
(upstreamthetranslationstartsitesandintrons).Indeed,the
identiﬁcation of nucleotide variations in putative or already
known regulatory sequences, within non-coding genomic
regions, is therefore of great relevance for future research.
This approach appears to be very promising above all for
the study of TFs binding sites, since their involvement in
human disease, both mendelian and multifactorial [135].
Barrio and colleagues (2009) [135] ﬁrst identiﬁed, by target
resequencing of a genomic region encompassing about 20kb,
non-coding variations associated with two kinds of red
cell aplasia, demonstrating that non-coding RPS19 gene
sequence variants contribute to the high clinical variability
observed in red cell aplasia. They hypothesized that speciﬁc
alleles in these non-coding regions may alter the binding of
regulatoryproteinsand/orTFs,possiblyalteringorremoving
an important stimulus for hematopoiesis [135].
In this context, the possibility to have high enrichment
for the both coding and unexplored regulatory regions
of PPARG, coupled to the targeted resequencing on NGS
platforms, will represent a very powerful approach for
researchers. Indeed, it is likely to allow the identiﬁcation
of all the potential risk-conferring variations, within its
coding regions, of putative novel single nucleotide variations
(mutations and SNPs) and insertions/deletions or other
genomic rearrangements, possibly associated to human
diseases. It will also allow gaining further insights into the
genomic architecture of its regulatory regions, oﬀering the
possibilitytorapidlyandaccuratelyidentifypotentialsources
of variation responsible for the alteration of its mRNA levels.
Moreover, the speciﬁc enrichment of target regions, followed
by targeted resequencing, could also be performed on well-
known PPARγ-regulated genes in speciﬁc pathways.
Indeed, since several studies performed on PPARγ target
genes have not unequivocally shown a clear correlation
between SNPs and the related human diseases, by using
these approaches it will be easier to identify speciﬁc alleles
in non-coding regions of target genes and verify whether
these nucleotide variations are responsible for the alteration
of known PPRE—and in turn of PPARγ binding to these
elements—ﬁnding a direct and functional link to the disease.
4.2.TranscriptionFactorsandChIP-Seq. Thankstotheintro-
duction of NGS platforms, widely used approaches of chro-
matin immuno-precipitation followed by microarray (ChIP-
chip) have been ﬂanked—and in many cases substituted—by
ChIP-seqprotocols.Indeed,inChIP-seq,theDNAfragments
of interest (i.e., binding sites for a TF) are directly sequenced
instead of being hybridized on a chip-array. Thanks to the
high resolution, coverage, the wider dynamic range, and
theabsenceofhybridization-based artifacts,ChIP-Seqallows
now researchers to improve both quantity and quality of
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more accurate deﬁnition of the consensus sequences for the
binding of TFs have been done [136].
To date, this novel approach, which couples in a single
experiment a standard ChIP assay to the large-scale massive
sequencing of target genome regions, allows researchers
to obtain a more complete map of TFs-DNA interactions
[2]. Drawing a precise map of TFs binding sites, core
transcriptional machinery, and other DNA-binding proteins
is a crucial step towards the identiﬁcation of gene regulatory
networks underlying physiological as well as pathological
processes [136].
In particular, since PPARγ acts in combination with
RXR as heterodimer and requires the cooperation with
many diﬀerent tissue-selective factors, understanding the
diﬀerential spatial and temporal recruitment of PPARγ:RXR
complex to target genes is likely to improve our knowledge
about PPARγ biology.
In a recent study, Nielsen et al. [28] by ChIP-Seq on
NGS platform (Illumina, Roche) obtained a PPARγ-a n d
RXR-binding sites map during the adipocytes diﬀerentiation
of 3T3-L1 cells [28]. In particular, they sequenced a total
of about 86 million of fragments (divided for the six days
of the analysis on the adipocytes) derived from PPARγ
ChIP assay and about 50 million derived from RXR ChIP.
They demonstrated that spatial and temporal recruitment of
PPARγ and RXR to target genes varied during adipogenesis
(Figure 1). More in detail, they observed that in the very
early stages of adipocyte diﬀerentiation, coinciding with the
v e r yl o wl e v e l so fP P A R γ at day 0, only nine PPARγ target
sites were detectable, and however this number remained
low at day 1. In contrast, a high DNA occupancy by RXR
alone was detected. More interestingly, going on with the
diﬀerentiation process, most of these sites become occupied
by PPARδ:RXR complexes. A subsequent switch—starting
at day 2—between PPARδ and PPARγ, which becomes the
main RXR partner throughout the adipogenesis, coincided
with a signiﬁcant increase in both PPARγ1a n dP P A R γ2
expression [28–30]. They identiﬁed >5000 high-conﬁdence
PPARγ:RXR-binding sites in adipocytes coinciding to the
majority of induced genes. In silico analysis allowed to
observe that binding occurs in the proximity of genes
involved in lipid and glucose metabolism. The highest
number (about 7000) of PPARγ:RXR-binding sites was
observed at day 6. This genome-wide ChIP-Seq analysis
allowed to conﬁrm the binding of PPARγ:RXR heterodimer
to well-established PPREs in already known target genes. In
addition, novel target sites in introns of diﬀerent genes were
also identiﬁed.
ChIP-Seq was also recently used by Lefterova and col-
leagues (2010) [31] to address a critical issue aﬀecting several
reports about PPARγ function, the speciﬁcity of action, that
is, how PPARγ modulates target genes in some cell types but
not others. By using this innovative approach, the authors
determined which cell-type-speciﬁc cofactors are recruited
by PPARγ in mouse macrophages and adipocytes [31].
Indeed, it has been widely demonstrated the PPARγ transac-
tivation ability on target genes, with characteristic cell-type
speciﬁc patterns of gene modulation, but the molecular basis
of such a speciﬁcity has not yet been fully understood.
As generally assumed for other TFs, it has been pos-
tulated that its cell-type speciﬁcity might be due to a
diﬀerential binding to consensus sequences in the regu-
latory regions of target genes or a diﬀerential ability to
recruit chromatin remodelling enzymes [38]. The authors
identiﬁed a speciﬁc molecular signature of PPARγ binding,
by massively sequencing—overall the mouse genome—the
regions directly bound by PPARγ. This analysis revealed
that PPARγ cooperates with some cell-type-speciﬁc factors,
PU.1 and C/EBPβ, in the deﬁning the speciﬁcity of action
for PPARγ in each cell type (macrophages and adipocytes,
resp.) (Figure 1). PPARγ in macrophages binds uniquely at
genomic sites located in the proximity of immunity-related
genes and speciﬁcally colocalizes with PU.1 in areas of open
chromatin and in presence of histone acetylation whereas, in
preadipocytes, the presence of a repressive histone signature
excludes PPARγ from macrophage-speciﬁc sites. In this
case it has been shown that PPARγ is able to open the
chromatin and increase histone acetylation at adipocyte-
speciﬁc genomic sites. This paper demonstrates that, at least
in these cell types, the transcriptional regulation exerted by
PPARγ is attributed to a diﬀerential recruitment of speciﬁc
cofactors functioning as scaﬀolds for chromatin remodelling
enzymes.
Above described works have clearly shown the great
potential of sequencing-based ChIP assays, which do not
require ap r i o r iinformation about the genomic position
of TFs binding sites and allow to generate high-resolution
binding maps in response to a speciﬁc stimulus [123, 124].
However, as demonstrated in a recent work by Reddy and
colleagues (2009) [125], coupling ChIP-Seq to RNA-Seq
(described in detail in the next paragraph) for studying the
response of a TF to a speciﬁc drug allows to examine well-
known models at much greater depth and detail. In partic-
ular, they obtained a comprehensive map of glucocorticoid
receptor binding to DNA overall the genome by ChIP-Seq,
and measured related changes in gene expression by RNA-
Seq, in response to treatment with dexamethasone [125].
We ﬁrmly believe that combining a sequencing-based
ChIP assay to high-throughput transcriptome analysis by
RNA-Seq on NGS platforms, above all for inducible tran-
scription factors (and PPARγ among them), will surely
p r o v i d eac o m p l e t e ,a c c u r a t e ,a n dr e l i a b l es o u r c eo fu s e f u l
of data, enabling to complete, piece by piece, the intricate
puzzle of PPARγ functions.
4.3. Discovering the Transcriptional Landscape through RNA-
Seq. Since the end of the 90s the term “transcriptome” was
used to describe the identity of each expressed gene in a
speciﬁc cell type and/or tissue/organ/organism, and of its
related transcriptional levels [137]. It was ﬁrst believed to
consist of 80–90% of ribosomal RNA (rRNA), 5–15% of
transfer RNA (tRNA), and the remaining fraction of mes-
senger RNA (mRNA), with most of the genome consisting of
untranscribed and genetically inert regions.
In contrast, recent evidences have shown that both
intragenic and intergenic sequences cannot be any longer
considered as “junk DNA”, but they represent one of the12 PPAR Research
main driving force accounting for diversity and biological
complexity of all living organisms [121]. Indeed, several
studieshavedemonstratedanunexpectedlevelofcomplexity
of the eukaryotic transcription, showing its pervasive nature
with almost the full length of nonrepeat regions of the
genome being transcribed [138, 139].
Hence, interpreting the complexity of a whole transcrip-
tome is likely to be a crucial endpoint for unraveling the role
of functional elements of a genome, and, in light of this,
the introduction of NGS platforms has provided researcher
a powerful tool for analysis in a single experiment.
Indeed, the rapid diﬀusion of RNA-Seq protocols has
raisedthepossibilitytoquantifythediﬀerentialexpressionof
transcripts in both physio- and pathological conditions and
to identify and characterize all the transcripts (both protein-
coding and non-coding) expressed within a speciﬁc cell
and/or tissue—at a particular development stage or after an
endogenous or exogenous stimulus—correctly determining
the splicing and the structure of genes. Unlike hybridization-
based gene expression methods (microarray) and tag-based
sequencing (i.e., CAGE and SAGE), RNA-Seq does not
require prior knowledge of any gene sequence (as occurs
for microarrays) or laborious and time-consuming steps for
the cloning and sequencing (as occurs for existing tag-based
approaches) (reviewed in [121]).
Several recent studies have clearly demonstrated the
advantages of using RNA-Seq in the interrogation of tran-
scriptomes under multiple conditions, such as cell prolifera-
tion, diﬀerentiation, and various environmental stress [140–
148].
In this context, due to the crucial role of PPARγ as TF
involvedinmanycellularpathways,investigatingthePPARγ-
dependentregulationoftargetgenesexpressionviaRNA-Seq
in a single experiment represents a great challenge.
Whereas previously described ChIP-Seq allows to draw
a binding map of PPARγ to PPRE, activating or repressing
target gene expression, directly identifying (by RNA-Seq)
the gene expression response to PPARγ-modulating drugs
(agonists such as TZD), or in particular development con-
ditions (during adipogenesis), will provide researchers the
opportunity to directly measure its ability to modulate the
transcriptionofspeciﬁcgenesinacell/tissuespeciﬁcmanner.
Since high-throughput sequencing has deﬁnitely proved
to be a powerful and quantitative method to sample the
transcriptomes at single nucleotide resolution [149], the use
of RNA-Seq is likely to shed a new light on the speciﬁcity
of action of PPARγ in diﬀerent cell types or tissue, in both
physiological and pathological conditions. Several unsolved
questionsaboutthe“real”impactofPPARγ ontheregulation
of target gene expression—in several conditions—can now
be fruitfully addressed by the use of NGS.
5. Concluding Remarks
Over the past years, PPARs, and especially PPARγ,h a v e
emerged as crucial transcription factors modulating the
expression of genes involved in several important pathways
andbiologicalprocessesand,noteworthy,inhumandiseases.
Despite the huge knowledge in the ﬁeld, future research
eﬀorts will undoubtedly reveal novel mechanisms through
which PPARγ integrates these complex physiological and
pathological pathways. Particular attention should be given
to the question of how the selective eﬀects of PPARγ are
achieved in diﬀe r e n tc e l lt y p e s .I tw i l la l s ob eo fg r e a t
importance to understand the subtle mechanisms dictating
this selectivity of action through the study of its diﬀerent
isoforms, genetic variations, and their recruited cofactors
able to remodel the chromatin structure. Knowing all the
PPARγ targets is a prerequisite for a full understanding of
themetabolicdefectsthatoccurinpeoplewithPPARGmuta-
tions and/or variation and will help in the interpretation of
eﬀects—and also side eﬀects—that can occur with PPARγ
agonists already in clinical use. Thus, to have a complete
picture of PPARγ functions and implications, studying
altogether these aspects, through the use of massively
parallel sequencing platforms, will provide a way to better
characterize the actions of PPARG products and agonists.
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